Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factorsRaffaella Bucciardini, Marco Floridia, Gabriella d’Ettorre et al.|International Journal of STD & AIDS|2012Cited by 10
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfectionLE Weimer, Giovanni Guaraldi, Nicoletta Ladisa et al.|Journal of Antimicrobial Chemotherapy|2012Cited by 10